Brainsway Ltd
Research Brainsway Ltd (BWAY) on Bullrun: valuation model: 10.1% overvalued, market cap USD 472.32M, P/E 49.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBWAY
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal10.1% overvalued
- Market capUSD 472.32M
- P/E49.6
- Financial periodQ2 2026
- RevenueUSD 17.11M
- Net incomeUSD 2.71M
- Free cash flowUSD 5.42M
- Gross margin74.6%
Valuation Snapshot
Bullrun's latest valuation model marks Brainsway Ltd as 10.1% overvalued; latest market cap is USD 472.32M; P/E is 49.6.
Peer valuation comparison
Latest P/E is 49.56x versus a Healthcare sector median of 24.61x (101.4% above).
Latest P/E is 49.56x versus a Israel median of 24.85x (99.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 52.23M | USD 7.63M | USD 16.27M | 75.4% | 0.18 | USD 67.70M | USD 6.82M | USD 73.22M |
| FY2024 | USD 41.02M | USD 2.92M | USD 6.50M | 74.6% | 0.09 | USD 69.35M | USD 5.62M | USD 62.31M |
| FY2023 | USD 31.79M | -USD 4.20M | -USD 1.10M | 73.9% | -0.13 | USD 10.52M | USD 471.00K | USD 41.58M |
| FY2022 | USD 27.18M | -USD 13.35M | -USD 9.76M | 73.8% | -0.4 | USD 47.58M | USD 488.00K | USD 45.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 472.32M | 49.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 372.42M | 45.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 177.60M | 39.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 107.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 126.71M | n/a | n/a | n/a |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Brainsway Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Brainsway Ltd as 10.1% overvalued.
What is Brainsway Ltd's market cap?
Brainsway Ltd's market capitalization is USD 472.32M.
What is Brainsway Ltd's P/E ratio?
Brainsway Ltd's price-to-earnings (P/E) ratio is 49.6.
What does Brainsway Ltd do?
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.